Board Member
Repligen Corp (RGEN)Board Member
Orasure Technologies Inc (OSUR)Equibles does not estimate personal net worth.
Get an email with a short summary when Repligen Corp publishes a filing, an earnings call transcript or a press release.
Get RGEN alertsCarrie Eglinton Manner is recorded as Board Member at Repligen Corp (RGEN), Board Member at Orasure Technologies Inc (OSUR) since January 1, 2022 and CEO at Orasure Technologies Inc (OSUR). The newest filing on record that lists Carrie Eglinton Manner as Board Member at Repligen Corp (RGEN) is dated April 2, 2026. The newest filing on record that lists Carrie Eglinton Manner as CEO and Board Member at Orasure Technologies Inc (OSUR) is dated April 30, 2026. Orasure Technologies Inc reported in an 8-K filed May 14, 2025 that Carrie Eglinton Manner was appointed Class I Director, effective May 14, 2025. The proxy statement of Orasure Technologies Inc reports total compensation of $4,292,228 for Carrie Eglinton Manner in fiscal 2025, including a base salary of $721,000. Disclosed compensation is on record for 6 fiscal years. Carrie Eglinton Manner has spoken on 12 earnings calls across 1 company, most recently for Orasure Technologies Inc on August 5, 2026. Orasure Technologies Inc is classified in the Medical Instruments & Supplies industry within the Healthcare sector. Repligen Corp is classified in the Medical Instruments & Supplies industry within the Healthcare sector. Other leadership on record at Orasure Technologies Inc includes Nancy Gagliano (CEO and Board Member), John P. Kenny (Chairman and Board Member), Mara Aspinall (Chairman) and 7 others.
“ITEM 1. Election of Three Class I Directors for Terms Ending in 2028.”
“Today I'll discuss some of the highlights from Q2 and provide updates on our key priorities for 2026. Q2 was another important quarter in Orishore's transformation.”
“Today, I'll discuss some highlights from Q1 and provide updates on our key priorities for 2026.”
“Today, I will discuss some highlights from Q3 and our progress on key priorities for 2025 and beyond. Overall, we continue to significantly advance our strategic transformation and execute with discipline as we position OraSure for a return to growth in 2026.”
“We are pleased to provide an update on the progress OTI is making on the three pillars of our strategic transformation: one, strengthening our foundation; two, elevating our core growth; and three, accelerating profitable growth.”
“We are pleased to provide an update on the progress OraSure is making on the three pillars of our transformation: one, strengthening our foundation two, elevating our core growth and three, accelerating profitable growth.”
2022-01-01–present
Last confirmed April 30, 2026
Start not stated–present
Last confirmed April 2, 2026
Start not stated–present
Last confirmed April 30, 2026
Proxy statement
Start not stated–2022-06-03
Medical Instruments & Supplies · Healthcare
CEO, Board Member
2022-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Orasure Technologies Inc (OSUR) | President and Chief Executive Officer | $721,000 | $4,292,228 |
| 2024 | Orasure Technologies Inc (OSUR) | President and Chief Executive Officer | $721,000 | $5,602,298 |
| 2023 | Orasure Technologies Inc (OSUR) | President and Chief Executive Officer | $721,000 | $6,701,767 |
| 2022 | Orasure Technologies Inc (OSUR) | President and Chief Executive Officer | $376,923 | $6,746,923 |
| 2022 | Quest Diagnostics Inc (DGX) | Former Senior Vice President, Advanced and General Diagnostics and Clinical Solutions | $270,673 | $4,211,531 |
| 2021 | Orasure Technologies Inc (OSUR) | President and Chief Executive Officer | — | — |
| 2021 | Quest Diagnostics Inc (DGX) | Former Senior Vice President, Advanced and General Diagnostics and Clinical Solutions | $600,000 | $3,324,676 |
| 2020 | Orasure Technologies Inc (OSUR) | President and Chief Executive Officer | — | — |
| 2020 | Quest Diagnostics Inc (DGX) | Former Senior Vice President, Advanced and General Diagnostics and Clinical Solutions | $566,538 | $3,278,981 |
